Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AMERICAN CRITICAL CARE WILL MARKET I.V. NICARDIPINE AND DIPHENYLHYDANTOIN PRODRUG

Executive Summary

American Critical Care will market Syntex' I.V. nicardipine and Merck's prodrug of diphenylhydantoin under separate licensing agreements announced Aug. 5. American Hospital Supply Corp.'s hospital drug marketing division said in a press release that "under agreement with Syntex U.S.A., American Critical Care will develop and market an injectable form of nicardipine, a calcium channel blocker used to treat hypertension, congestive heart failure and angina." American Critical Care added that it has already begun clinical development of nicardipine and "will provide Syntex with data for the NDA filing." In June, Syntex began filing its NDA for oral nicardipine with the submission of the chemistry and pharmacy sections of the application under FDA's new expedited format, Syntex Chairman Albert Bowers, PhD, reported at a recent presentation to analysts. Under the NDA rewrite regulations, companies can now submit the chemistry and pharmacy section of an NDA 90-120 days in advance of the remainder of the application. Bowers told the analysts that the company expected to have the remainder of the NDA submission completed by the end of the summer. Nicardipine is licensed from Yamanouchi. Nicardipine I.V. would be the second important injectable cardiovascular drug in American Critical Care's pipeline. The firm's internally developed injectable beta blocker Brevibloc (esmolol) is currently pending approval at FDA following submission of an NDA in late 1984. American Critical Care noted that Brevibloc has been classifed 1-A (new chemical entity representing an important therapeutic advancel by FDA. When approved, Brevibloc will be the "only titratable ultra-short-acting beta blocker available" for the acute care setting, the firm said. The AHSC subsidiary's agreement with Merck covers both development and marketing of the prodrug of diphenylhydantoin. "The prodrug is expected to improve the solubility and stability of injectable diphenylhydantoin, used for control of epilepsy," the release points out. Current marketers of phenytoin I.V. include Parke-Davis (Dilantin) and Elkins-Sinn. American Critical Care added that it is "also expanding its efforts to bring a broad line of generic drugs to hospitals to take advantage of the high growth in the generic drug marketplace."

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
UsernamePublicRestriction

Register

PS008756

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel